LYMPHOMA, LARGE-CELL, ANAPLASTIC
Clinical trials for LYMPHOMA, LARGE-CELL, ANAPLASTIC explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, LARGE-CELL, ANAPLASTIC trials appear
Sign up with your email to follow new studies for LYMPHOMA, LARGE-CELL, ANAPLASTIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lymphoma drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: LYMPHOMA, LARGE-CELL, ANAPLASTIC
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Matched conditions: LYMPHOMA, LARGE-CELL, ANAPLASTIC
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC